Condition: Abnormal Uterine Bleeding Due to Adenomyosis (Disorder) · Sponsor: University Hospital, Bordeaux
The present study aims to compare the efficacy (menstrual blood loss, pain, quality of life) and the safety (complications, recovery) of each conservative intervention (RFA, UAE) versus hysterectomy for the treatment of adenomyosis-related abnormal uterine bleeding, up to 2 years
This description comes directly from the study's public registry record.
Jean-Luc Brun, MD, PhD · +33 5 56 79 59 85 · jean-luc.brun@chu-bordeaux.fr
Marc Sapoval, MD, PhD · +33 1 56 09 37 41 · marc.sapoval2@aphp.fr
Always discuss trial participation with your own doctor first.
| CHU Bordeaux | Bordeaux, France | Not Yet Recruiting |
| APHP - Hôpital Antoine Béclère | Clamart, France | Not Yet Recruiting |
| CHU Limoges | Limoges, France | Not Yet Recruiting |
| CHU Montpellier | Montpellier, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07195305